Osmol Therapeutics is a privately held biopharma focused on developing OSM-0205, a drug candidate to prevent chemotherapy-induced peripheral neuropathy (CIPN) based on Dr. Barbara Ehrlich’s research in neuronal calcium sensor-1 (NCS1) in-licensed from Yale University. Preclinical data conducted by Osmol show that pre-treatment with OSM-0205 prevents the pathologic damage caused by taxanes and potentially other chemotherapy agents. The company announced closing of the first $5.2 million tranche of a $7.5 million Series A-1 financing led by Koax Investment Partners, a fund formed by the founders of Biohaven Pharmaceuticals. The first tranche will allow Osmol to complete IND-enabling studies and to file an Investigational New Drug (IND) application later this year. The remaining capital from the Series A-1 is intended to fund a Phase 1 bioavailability trial in the first half of 2023 and support initiation of a Phase 2 proof-of-concept clinical study in mid-2023. Osmol also plans to pursue a second indication for chemotherapy-induced cognitive impairment ("chemobrain"). The company is based in New Haven, Conn., and notes there are currently no FDA-approved therapies for prevention or treatment of CIPN.

Total raised

$5M

Funding rounds

1

Latest round

Series A

Latest activity

Apr 2022